

Jonathan H. Schatz, MD

Professional address and telephone: University of Arizona Cancer Center
1515 N Campbell Avenue, Tucson, AZ, 85724
schatzj@email.arizona.edu
520-626-2272 (office), 520-626-2217 (laboratory)

Chronology of Education/Training

2000-2004 University of Chicago Pritzker School of Medicine, MD
2004-2007 University of Chicago Hospitals, Internship/Residency in Internal Medicine
2007-2010 Memorial Sloan-Kettering Cancer Center, Fellowship in
Hematology/Medical Oncology

Chronology of Employment

2010-2012 Memorial Sloan-Kettering Cancer Center, Clinical Instructor,
Department of Medicine
2012-Present University of Arizona, Assistant Professor of Medicine, Bio5 Institute
Investigator, Clinical & Translational Science Institute
Cross-Appointment, Dept. of Pharmacology & Toxicology

Medical Licensure Arizona (#46396)

Board Certification (ABIM #279487)

2007 Internal Medicine
2010 Medical Oncology

Honors and Awards

1998 Illinois Associated Press Editors Association Editorial Excellence Contest
First Place, Investigative Reporting
2001 NIH Student Summer Research Award
2003 Calvin Fentress Research Fellowship Award
2004 University of Chicago Pritzker School of Medicine, Leon O. Jacobson Prize: Best
presentation at the Senior Scientific Session of research done in medical

- school by a non-Ph.D. student in the area of basic science investigation
- 2005 American College of Physicians, Northern Illinois Chapter Scientific Meeting
First Place, Resident Poster Competition
- 2009 Memorial Sloan-Kettering Cancer Center, Mortimer J. Lacher Fellowship
- 2011 Leukemia & Lymphoma Society Career Development Program, Selected as Special
Fellow in Clinical Research (funding declined due to overlap)

Institutional Activities

- 2013-Present Arizona Health Sciences Center Precision Health Advisory Council
- 2012-Present UA Cancer Center Scientific Review Committee, voting member
- 2012-Present UA Lymphoma Clinical Service, practitioner and researcher
- 2010-2012 MSKCC Lymphoma Disease Management Team
- 2011-2012 MSKCC Peripheral T-Cell Lymphoma Working Group (founding member)
- 2011-2012 MSKCC Molecular Pathology Clinical Testing Advisory Group

Memberships/Activities

- 2008-Present American Society of Clinical Oncology
- 2008-Present American Association for Cancer Research
- 2009-Present American Society of Hematology
- 2012-Present Lymphoma Research Foundation, Scientific Advisory Panel
- 2012-Present Member, Southwest Oncology Group (SWOG ID# 48561)
-Committees: Lymphoma, Early Therapeutics

Journal Reviewer: *Blood*

Publications

Odejide O, Weigert O, Lane AA, Toscano D, Lunning MA, Kopp N, Kim S, van Bodegom D, Bolla S, **Schatz JH**, Teruya-Feldstein J, Hochberg E, Louissaint A, Dorfman D, Stevenson K, Rodig SJ, Piccaluga PP, Jacobsen E, Pileri SA, Harris NL, Ferrero S, Inghirami G, Horwitz SM, Weinstock DM. A Targeted Mutational Landscape of Angioimmunoblastic T-cell Lymphoma. *Blood*. In press.

Schatz JH, Oricchio E, Puvvada SD, Wendel HG. Progress Against Follicular Lymphoma. *Current Opinion in Hematology*. Curr Opin Hematol. 2013 Jul;20(4):320-6.

Schatz JH, Oricchio E, Wolfe AL, Jiang M, Linkov I, Maragulia J, Shi W, Zhang Z, Vinagolu RK, Pagano NC, Porco JA, Teruya-Feldstein J, Rosen N, Zelenetz AD, Pelletier J, Wendel HG. Targeting

cap-dependent translation blocks converging survival signals by AKT and PIM kinases in lymphoma. *J Exp Med*. 2011 Aug 29;208(9):1799-807.

Schatz JH, Wendel HG. Targeted Cancer Therapy: What if the Driver is Just a Messenger? *Cell Cycle*. 2011 Nov 15;10(22):3830-3.

Oricchio E, Nanjangud G, Wolfe AL, **Schatz JH**, Mavrakis KJ, Jiang M, Liu X, Bruno J, Heguy A, Olshen AB, Socci ND, Teruya-Feldstein J, Weis-Garcia F, Tam W, Shaknovich R, Melnick AM, Himmanen J, Chaganti RSK, Wendel HG. The Eph-Receptor A7 Is a Soluble Tumor Suppressor for Follicular Lymphoma. *Cell*. 2011;147(3):554-64.

Schatz JH. Targeting the PI3K/AKT/mTOR Pathway in Non-Hodgkin Lymphoma: Results, Biology, and Development Strategies. *Curr Oncol Rep*. 2011 Oct;13(5):398-406.

Oricchio E, Wolfe AL, Mavrakis KJ, **Schatz JH**, Wendel HG. Mouse models of cancer as biological filters for complex genomic data. *Dis Model Mech*. 2010 Nov-Dec; 3(11-12):701-4.

Jo SH*, **Schatz JH***, Acquaviva J*, Singh H, Ren R. Cooperation between deficiencies of IRF-4 and IRF-8 promotes both myeloid and lymphoid tumorigenesis. *Blood*. 2010 Oct 14; 116(15):2759-67. *These authors contributed equally to this work.

Jhaveri KD, **Schatz JH**, Young JW, Flombaum C. Sirolimus (rapamycin) induced proteinuria in a patient undergoing allogeneic hematopoietic stem cell transplant. *Transplantation*. 2008 Jul 15; 86(1):180-1.

Sciammas R, Shaffer AL, **Schatz JH**, Zhao H, Staudt LM, Singh H. Graded expression of interferon regulatory factor-4 coordinates isotype switching with plasma cell differentiation. *Immunity*. 2006 Aug; 25:225-36.

Submitted Manuscripts

Oricchio E, **Schatz JH**, Ciriello G, Jiang M, Maragulia J, Heguy A, Viale A, de Stanchina E, Teruya-Feldstein J, Sander C, Tam W, Chaganti RSK, Wendel HG. A Novel Combination Therapy Based On The Genetics Of Follicular Lymphoma. Manuscript submitted.

Wolfe AL, Mavrakis KM, Van Der Meulen, **Schatz JH**, Jiang M, Van Roy N, de Stanchina E, Teruya-Feldstein J, Speleman F, Porco JA, Pelletier J, Wendel HG. The 5' untranslated region (UTR) of many oncogenes and transcription factors encodes a targetable dependence on the eIF4A RNA helicase Manuscript submitted.

Scholarly Presentations

2013, Oral session, American Society of Hematology Annual Meeting, Title: "Next-Generation Sequencing Suggests Complex, Heterogeneous Pathogenesis in Peripheral T-Cell Lymphoma Unspecified"

2013, Oral session, International Congress on Malignant Lymphoma, Lugano, Switzerland, Title: "Next-Generation Sequencing Suggests Therapeutic Targets in Peripheral T-Cell Lymphoma"

2011, Oral session, International Congress on Malignant Lymphoma, Lugano, Switzerland, Title: "Targeting Cap-Dependent Translation to Bypass AKT and the PIM Family Kinases in Non-Hodgkin Lymphoma"

2010, Oral session, American Society of Hematology Annual Meeting, Title: "Targeting Translation Bypasses Pim Kinase Activity, a Common and Adverse Prognostic Marker in Lymphoma"

2010, Poster and abstract, Mechanisms & Models of Cancer (Cold Spring Harbor), Title: "Targeting Translation Bypasses Pim Kinase Activity, a Common and Adverse Prognostic Marker in Lymphoma"

2009, Poster and abstract, American Society of Hematology Annual Meeting, Title: "Oncogenic Pim Kinase Activity Provides Resistance to mTor Inhibition In Vitro and In Vivo"

2006, Poster and abstract, American Society of Hematology Annual Meeting, Title: "IRF-4 Functions as a Myeloid Tumor Suppressor"

2004, Poster and abstract, American Society of Hematology Annual Meeting, Title: "Loss of IRF-4 Exacerbates CML-like Phenotype of IRF-8 Knockout Mice"

2004, Senior Scientific Forum, University of Chicago Pritzker School of Medicine, Title: "The Transcription Factors IRF-4 and IRF-8: New Insights on Myeloid Development and the Pathogenesis of Chronic Myeloid Leukemia"

2001, Summer Research Forum, U. of Chicago Pritzker School of Medicine, Title: "Interleukin 7 and B-cell differentiation, a mutational analysis of IL-7 receptor"

Research Support

Current Support:

Unnumbered (PI: Schatz), 8/13/12-8/12/17
University of Arizona, Clinical & Translational Science Institute, Laboratory Startup Funds
Multiple Projects

192191 (PI: Schatz), 4/15/11-4/14/14, \$75,000/year

Lymphoma Research Foundation Career Development Award
Targeting Cap-Dependent Translation to Improve Outcomes in Non-Hodgkin Lymphoma

Unnumbered (PI: Horwitz), 9/1/11-8/31/14, \$100,000/year
Cycle for Survival Research Grant (MSKCC)
Identification of Novel Therapeutic Targets in Mature T-Cell Lymphomas Through Functional, Genomic, and Immunologic Characterization

P30CA023074-34 sub-award (PI: Schatz), 7/1/13-6/30/14, \$30,000/year
NIH/NCI Cancer Center Support Grant sub-award (University of Arizona Cancer Center)
Cyclin-Dependent Kinase Inhibition as a Synthetic Lethal Approach in High-Risk Diffuse Large B-Cell Lymphoma with Co-Expression of MYC and BCL2

IRG-74-001-35 sub-award (PI: Schatz), 7/1/13-6/30/14, \$15,000/year
American Cancer Society Institutional Research Grant sub-award
Defining a role for pan-PIM kinase inhibition in non-Hodgkin lymphoma

Past Support:

Federal:

NIH Student Summer Research Award, 2001

NIH T32 Training Grant (CA009207-32) 2008-2009. PI: Dean Bajorin

Private Foundation:

Calvin Fentress Research Fellowship Award, University of Chicago Pritzker School of Medicine, 2003-2004

American Society of Clinical Oncology, Young Investigator Award, \$50,000 one-year award, 2009-2010, Principal Investigator: Jonathan Schatz, 90 percent effort

Clinical Scholars Biomedical Fellowship, Sloan-Kettering Institute for Cancer Research, \$93,000 two-year award, 2009-2011, Principal Investigator: Jonathan Schatz, 90 percent effort

MSKCC Translational and Integrative Medicine Research Fund, \$100,000 one-year award, 2011, Principal Investigator: Jonathan Schatz, 75 percent effort

Gabriel's Angel Foundation Award, \$25,000 one-time award, March 2011, Principal Investigator: Jonathan Schatz, percent effort N/A